Scarica l'app Stockscreener
8.81
5.17%
-0.48
Dopo l'orario di chiusura:
8.94
0.13
+1.48%
Precedente Chiudi:
$9.29
Aprire:
$9.23
Volume 24 ore:
1.54M
Relative Volume:
0.57
Capitalizzazione di mercato:
$520.74M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
168.13
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+11.66%
1M Prestazione:
+44.66%
6M Prestazione:
+95.34%
1 anno Prestazione:
+79.07%
Intervallo 1D:
$8.67
$9.42
Intervallo di 1 settimana:
$7.70
$9.94
Portata 52W:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
8.81 | 520.74M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Iniziato | Truist | Buy |
| 2025-11-05 | Iniziato | B. Riley Securities | Buy |
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
CEO Moves: Why is Vanda Pharmaceuticals Inc stock going up2026 Market Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st
Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada
VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - TipRanks
Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug - Stock Titan
Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week HighWhat's Next? - MarketBeat
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 8.1%Should You Buy? - MarketBeat
Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia - MSN
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline By Investing.com - Investing.com Australia
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat
Executive at Vanda (NASDAQ: VNDA) sells shares to cover RSU taxes - Stock Titan
[Form 4] Vanda Pharmaceuticals Inc. Insider Trading Activity - Stock Titan
Vanda (NASDAQ: VNDA) CEO sells 156,235 shares to cover RSU tax obligations - Stock Titan
Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 Earnings Estimate for VNDA Issued By HC Wainwright - MarketBeat
VNDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News
FDA Grants Rare Hearing for Vanda Pharmaceuticals' (VNDA) Jet La - GuruFocus
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals
Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com
Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com
Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - ChartMill
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Document - SEC.gov
EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights
Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com
Vanda Pharmaceuticals Announces Participation in the 2026 Citize - GuruFocus
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill
A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: A Biotech Contender with Nearly 80% Upside Potential - DirectorsTalk Interviews
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):